PAH

Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug
BioSpace
Thu, 09/30/21 - 12:01 am
Merck
Acceleron
M&A
PAH
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
Endpoints
Tue, 09/28/21 - 12:15 am
Merck
Acceleron
M&A
PAH
sotatercept
MannKind and United Snag Priority Review for Pulmonary Hypertension Drug
BioSpace
Wed, 06/16/21 - 11:17 pm
MannKind
United Therapeutics
PAH
PH-ILD
FDA
priority review
Tyvaso
Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Endpoints
Wed, 05/19/21 - 10:42 am
Acceleron
sotatercept
PAH
J&J aims to create community for PAH patients and their doctors with new Uptravi campaign
Fierce Pharma
Tue, 05/18/21 - 10:59 am
JNJ
PAH
Uptravi
pharma marketing
United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback
Endpoints
Wed, 03/3/21 - 10:57 am
United Therapeutics
Trevyent
PAH
SteadyMed
With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso
Endpoints
Mon, 12/28/20 - 10:47 am
United Therapeutics
Tyvaso
priority review voucher
PAH
Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients
Pharmaceutical Business Review
Tue, 09/8/20 - 10:43 am
Adempas
Bayer
PAH
clinical trials
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Endpoints
Wed, 04/8/20 - 10:37 am
Acceleron
PAH
FDA
breakthrough therapy
sotatercept
Reata Pharmaceuticals Says Ongoing Trials In Patients With Pulmonary Arterial Hypertension Stopped Due To High Risk Of COVID-19 To These Patients
Reuters
Mon, 03/30/20 - 08:18 pm
Reata Pharmaceuticals
PAH
clinical trials
COVID-19
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Tue, 01/28/20 - 11:09 am
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
Motley Fool
Mon, 01/27/20 - 10:47 pm
Acceleron
PAH
clinical trials
sotatercept
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
Pharmaceutical Business Review
Tue, 09/10/19 - 11:06 am
Acceleron
orphan drugs
sotatercept
PAH
United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug
BioSpace
Fri, 04/19/19 - 05:53 pm
United Therapeutics
PAH
Remodulin
generics
Sandoz
United Therapeutics tosses out esuberaprost after trial flop
Fierce Biotech
Mon, 04/8/19 - 09:59 am
United Therapeutics
PAH
esuberaprost
clinical trials
Targeting underlying cause of PAH, Cambridge spinout Morphogen-IX raises about $23M in Series B
Endpoints
Wed, 12/19/18 - 12:26 am
PAH
Morphogen-IX
Actelion inks $360M deal to resolve DOJ kickbacks probe
Fierce Pharma
Thu, 12/6/18 - 06:54 pm
JNJ
DOJ
PAH
Actelion
kickbacks
Arena’s Comeback Continues with $800M Deal for Blood Disease Drug
Xconomy
Thu, 11/15/18 - 11:41 pm
Arena Pharmaceuticals
United Therapeutics
PAH
ralinepag
Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil
Endpoints
Tue, 09/4/18 - 09:43 am
MannKind
United Therapeutics
PAH
Treprostinil
Mylan Launches First Adcirca Generic, Stock Moves Up
Market Realist
Mon, 08/13/18 - 05:56 pm
Mylan
tadalafil
generics
PAH
Adcirca
United Therapeutics

Pages